Selecting medications for the treatment of urinary incontinence.

In response to the growing population of older patients with incontinence, pharmaceutical companies are developing new drugs to treat the condition. Before prescribing medications for incontinence, however, physicians should determine the nature and cause of the patient's incontinence. The evaluation should rule out reversible conditions, conditions requiring special evaluation, and overflow bladder. The best treatment for urge incontinence is behavior therapy in the form of pelvic floor muscle exercises. Medications, used as an adjunct to behavior therapy, can provide additional benefit. Many therapies are available for patients with stress incontinence, including pelvic floor muscle exercise, surgery, intravaginal support devices, pessaries, peri-urethral injections, magnetic chairs, and intraurethral inserts. No medication has been approved for the treatment of stress incontinence, although medications are under development.

[1]  A. Diokno,et al.  Ephedrine in treatment of urinary incontinence. , 1975, Urology.

[2]  J. Wyman,et al.  Bladder training in ambulatory care management of urinary incontinence. , 1991, Urologic nursing.

[3]  D. McClish,et al.  Estrogen Therapy in the Management of Urinary Incontinence in Postmenopausal Women: A Meta-Analysis. First Report of the Hormones and Urogenital Therapy Committee , 1994, Obstetrics and gynecology.

[4]  D. McClish,et al.  Efficacy of Estrogen Supplementation in the Treatment of Urinary Incontinence , 1996, Obstetrics and gynecology.

[5]  J. Hruschak Urinary Incontinence in Adults: Acute and Chronic Management , 1996 .

[6]  P. Goode,et al.  Pharmacologic treatment of lower urinary tract dysfunction in geriatric patients. , 1997, The American journal of the medical sciences.

[7]  David H. Thom Variation in Estimates of Urinary Incontinence Prevalence in the Community: Effects of Differences in Definition, Population Characteristics, and Study Type , 1998 .

[8]  T. Wagner,et al.  Economic costs of urinary incontinence in 1995. , 1998, Urology.

[9]  N. Resnick Improving treatment of urinary incontinence. , 1998, JAMA.

[10]  D. Lekan-Rutledge Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. , 1999, Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society.

[11]  M. Elhilali,et al.  Long–Term Effectiveness of Sacral Nerve Stimulation for Refractory Urge Incontinence , 2000, European Urology.

[12]  P. Sand,et al.  Update on extracorporeal magnetic innervation (EXMI) therapy for stress urinary incontinence. , 2000, Urology.

[13]  P. Goode,et al.  Combined Behavioral and Drug Therapy for Urge Incontinence in Older Women , 2000, Journal of the American Geriatrics Society.

[14]  R. Dmochowski,et al.  Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. , 2001, Mayo Clinic proceedings.

[15]  A. Wein,et al.  Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. , 2001, Urology.

[16]  M. Harvey,et al.  Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. , 2001, American journal of obstetrics and gynecology.

[17]  J. Blonski Is tolterodine (Detrol) or oxybutynin (Ditropan) the best for treatment of urge urinary incontinence? , 2001, The Journal of family practice.

[18]  W. Dimpfel,et al.  Effects of Tolterodine, Trospium Chloride, and Oxybutynin on the Central Nervous System , 2001, Journal of clinical pharmacology.

[19]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[20]  D. Roth,et al.  Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. , 2002, JAMA.

[21]  P. Herbison,et al.  Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. , 2002, The Cochrane database of systematic reviews.

[22]  G. Webster,et al.  Sacral neuromodulation in an older, urge-incontinent population. , 2002, American journal of obstetrics and gynecology.

[23]  M. Detke,et al.  Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. , 2002, The Journal of clinical psychiatry.

[24]  R. Dmochowski,et al.  Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. , 2002, The Journal of urology.

[25]  P. Norton,et al.  Duloxetine versus placebo in the treatment of stress urinary incontinence. , 2002, American journal of obstetrics and gynecology.

[26]  R. Wallace,et al.  Urinary Incontinence and Depression in Middle‐Aged United States Women , 2003, Obstetrics and gynecology.

[27]  R. Dmochowski,et al.  Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. , 2003, Mayo Clinic proceedings.

[28]  R. Dmochowski,et al.  Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. , 2003, Urology.

[29]  Oxybutynin transdermal (Oxytrol) for overactive bladder. , 2003, The Medical letter on drugs and therapeutics.

[30]  R. Dmochowski,et al.  Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. , 2003, The Journal of urology.

[31]  J. Ouslander,et al.  Management of Overactive Bladder , 2004, CNS Spectrums.

[32]  T. Wagner,et al.  Economic costs of urinary incontinence , 2005, International Urogynecology Journal.